Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment (Q33357697)

26 July 2017

Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment (English)

1 reference

26 July 2017

1 reference

Kim YJ

1

1 reference

26 July 2017

Kim DW

2

1 reference

26 July 2017

Lee S

3

1 reference

26 July 2017

Kim YL

4

1 reference

26 July 2017

Hwang JY

5

1 reference

26 July 2017

Park YH

6

1 reference

26 July 2017

Kim HJ

7

1 reference

26 July 2017

Lee JW

8

1 reference

26 July 2017

Min WS

9

1 reference

26 July 2017

Kim CC

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Bone Marrow Transplantation

26 July 2017

1 reference

26 July 2017

33

1 reference

26 July 2017

2

1 reference

26 July 2017

237-242

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704332

26 July 2017

0 references

cites work

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Characteristics of accelerated disease in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral bl

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Allele frequencies of 15 STR loci using AmpF/STR Identifiler kit in a Korean population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Cytogenetic patterns following bone marrow transplantation for chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Cytogenetics in patients with chronic myelogenous leukemia treated with bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704332

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704332

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference